Andere Sprachen Firebrick Pharma Limited

Aktien

A3DE5L

AU0000197352

FRE

Markt geschlossen - Australian S.E. Andere Börsenplätze 07:53:36 07.06.2024			% 5 Tage	% 1. Jan.
0,056 ^AUD	0,00 %		-6,67 %	+12,00 %

23.05.	Firebrick Pharma erhält Nasodine-Zusammensetzung Patent in Südafrika	MT
03.04.	Firebrick Pharma Phase 2 Covid-19 Studie im Laryngoscope Journal veröffentlicht	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Firebrick Pharma Obtains Nasodine Composition Patent in South Africa	23.05.
Firebrick Pharma Raises AU$800,000 via Placement	17.05.
Firebrick Pharma Appoints Auditor	06.05.
Firebrick Pharma's Nasodine Nasal Spray Enters US Market	17.04.
Firebrick Pharma Phase 2 Covid-19 Trial Published in Laryngoscope Journal	03.04.
Firebrick Pharma Gets Coverage Extension of COVID-19 Patent in US	04.03.
Firebrick Pharma Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28.02.
62,732,537 Ordinary Shares of Firebrick Pharma Limited are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	28.01.
Firebrick Pharma to Release Shares from Escrow; Shares Rise 4%	12.01.
Firebrick Pharma Withdraws Appeal Against Regulator's Decision Over Nasodine Nasal Spray	27.12.
Firebrick Pharma's Nasodine Nasal Spray COVID-19 Patent Granted in South Africa	29.11.
Firebrick Pharma Receives AU$1.8 Million R&D Tax Rebate	31.10.23
Firebrick Says Independent Probe Into Nasodine Trial Results Did Not Find Errors	04.10.23
Firebrick Pharma's Cold Medication Fails Phase III Trial	13.09.23
Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common Cold	13.09.23
Firebrick Pharma Limited Reports Earnings Results for the Full Year Ended June 30, 2023	29.08.23
Firebrick Pharma Completes Enrollment for Cold Treatment Trial; Shares Soar 17%	09.08.23
Firebrick Update on Administrative Appeals Tribunal Process	20.07.23
Firebrick Pharma's Nasal Spray Patent Allowed in Canada	09.05.23
Firebrick Pharma Raises AU$1 Million From Share Placement; Shares Slump 10%	01.05.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Firebrick Pharma Limited

Aktien

A3DE5L

AU0000197352

FRE

Andere Sprachen

Filter